Trials / Terminated
TerminatedNCT04159701
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3454738 is safe and effective as treatment for participants with hives that are caused by chronic spontaneous urticaria (CSU) and that are not controlled with H1-antihistamines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3454738 | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2019-11-15
- Primary completion
- 2021-02-24
- Completion
- 2021-02-24
- First posted
- 2019-11-12
- Last updated
- 2022-03-11
- Results posted
- 2022-03-11
Locations
25 sites across 3 countries: United States, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04159701. Inclusion in this directory is not an endorsement.